Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock
Close on Nov 12, 2026Market cap $65.95MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $65.95M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.78
- Dividend yield
- –
- Free cash flow yield
- -140.08%
Fundamentals
- Net income
- -$116.32M
- EPS, diluted
- -$6.09
- Free cash flow
- -$92.39M
- Book value per share
- $4.07
- Diluted shares
- 21M
Trading
- Next earnings
- Mar 8, 2027 (estimated, before the open)
- Previous close
- $4.00
- Open
- $4.00
- Day's range
- $3.23 – $4.01
- Volume
- 1,050,996
- Average volume (20 days)
- 1,154,452
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.45
- 52-week range
- $2.81 – $12.88
- RSI (14 days)
- 34.5
- Volatility (1 year)
- 79.9%
- Relative volume
- 1.24×
- WACC
- 12.2%
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CRBP | S&P 500 | Difference | CRBP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -35.3% | -2.7% | −32.6 pts | ||
| 3 months | -65.1% | -1.7% | −63.3 pts | ||
| Year to date | -58.1% | +11.9% | −70.0 pts | ||
| 1 year | -69.5% | +12.0% | −81.5 pts | ||
| 3 years | +4.9% | +78.2% | −73.3 pts | +1.6% | +21.2% |
| 5 years | -89.3% | +73.2% | −162.5 pts | -36.0% | +11.6% |
| 10 years | -98.1% | +309.6% | −407.7 pts | -32.6% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Corbus Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Update
About Corbus Pharmaceuticals
Pharmaceutical Preparations
Corbus Pharmaceuticals Holdings is a clinical-stage biopharmaceutical firm that develops treatments for oncology and metabolic conditions. Its pipeline includes CRB-701, an antibody-drug conjugate targeting Nectin-4 to treat solid tumors such as cervical, urothelial, and head and neck cancers. It also develops CRB-913, an oral cannabinoid receptor inverse agonist for obesity management. Because its programs remain in clinical testing, Corbus has no commercial products or commercial customers; its development efforts target patients suffering from advanced solid cancers and obesity.
Company profile, executives and historyCorbus Pharmaceuticals stock: common questions
What is Corbus Pharmaceuticals's stock price?
CRBP closed at $3.41 on Nov 12, 2026, down 14.75% on the day. Over the past 52 weeks it traded between $2.81 and $12.88.
What is Corbus Pharmaceuticals's market cap?
Corbus Pharmaceuticals was worth $65.95M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CRBP's P/E ratio?
Corbus Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$6.09), so it has no meaningful P/E ratio.
Does Corbus Pharmaceuticals pay a dividend?
No. Corbus Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Corbus Pharmaceuticals report earnings next?
Corbus Pharmaceuticals is expected to report Q4 FY2026 results on Mar 8, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CRBP stock performed over the past year?
Including dividends, CRBP returned -69.5% over the past year, against +12.0% for the S&P 500.
How many CRBP shares are sold short?
3M shares were sold short at the latest FINRA report, 17.29% of the float, or 3.5 days of average trading volume.
Who are Corbus Pharmaceuticals's competitors?
Companies most similar to Corbus Pharmaceuticals by business, industry and size include CNTX, SKYE, CRVS, RCUS, NAMS.
See a number that looks wrong?